Executive VP and CCO of $HBAN sells 17,200 shares in insider sale

In a recent move, Brendan A Lawlor, the Executive VP and CCO of $HBAN, made headlines by selling 17,200 shares of the company on 02-10-2026, generating an estimated $325,596. This transaction accounted for approximately 28.9% of Lawlor’s total shares in this class of stock, leaving him with 42,397 shares of $HBAN stock.

When delving into $HBAN’s insider trading activity, it is revealed that insiders have been actively trading this stock on the open market, with a total of 11 transactions taking place in the past 6 months. Of these trades, 1 was a purchase and 10 were sales. Noteworthy figures include MARCY C HINGST, who, as SEVP and General Counsel, made 3 sales of 60,348 shares, totaling $1,071,186, and HELGA HOUSTON, a Senior Exec. V. P., who sold 64,587 shares for an estimated $993,348. Lawlor himself made 2 sales of 17,454 shares, amounting to $330,425.

Moving on to $HBAN’s hedge fund activity, a significant number of institutional investors have either added or decreased their positions in the stock. Notable additions include DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN, which added 29,357,816 shares (+1005.9%) in Q3 2025, Vanguard Group Inc., which added 14,338,222 shares (+8.1%) in Q4 2025, and UBS AM, a distinct business unit of UBS Asset Management Americas LLC, which added 10,590,982 shares (+66.9%) in Q3 2025.

In terms of revenue, $HBAN reported revenues of $2.2B in Q4 2025, marking an 11.26% increase from the previous year. This positive growth trend is significant and reflects well on the company’s financial standing.

Congressional stock trading involving $HBAN has been limited, with members of Congress engaging in only 1 transaction in the past 6 months, which was a sale by SENATOR TINA SMITH on 11/21. Analyst ratings on $HBAN have been mixed, with 5 firms issuing buy ratings and 1 issuing a sell rating. Notable ratings include RBC Capital’s “Outperform” rating, Piper Sandler’s “Underweight” rating, and Evercore ISI Group’s “Outperform” rating.

Many analysts have provided price targets for $HBAN in recent months, with a median target of $20.5. Prominent targets include Vivek Juneja from JP Morgan with a target price of $21.0, Brian Foran from Truist Securities with a target price of $21.0, and David Konrad from Keefe, Bruyette & Woods with a target price of $19.5. These targets provide investors with valuable insights into the stock’s anticipated performance.

In conclusion, the insider sale by Brendan A Lawlor, along with the overall trading activity and financial indicators of $HBAN, presents a comprehensive picture of the company’s current standing and outlook. Interested parties can monitor these developments through Quiver Quantitative’s various tracking tools.